The Effect of Acarbose on Insulin Sensitivity in Subjects With Impaired Glucose Tolerance

OBJECTIVE To study the effect of acarbose, an α-glucosidase inhibitor, on postprandial plasma glucose and insulin and insulin sensitivity in subjects with impaired glucose tolerance (IGT). RESEARCH DESIGN AND METHODS Subjects with IGT were randomly treated in a double-blind fashion with placebo (n = 10) or acarbose (n = 8) at 100 mg t.i.d. for 4 months. All subjects were submitted before randomization and at the end of the study to a standardized breakfast and a 12-h daytime plasma glucose and plasma insulin profile, and insulin sensitivity was measured as steady-state plasma glucose (SSPG) using the insulin suppression test. RESULTS While placebo had no effect on postprandial plasma glucose and plasma insulin incremental area under the curve (AUC) (3.03 ± 0.5 vs. 3.76 ± 0.6 mmol·h−1 · l−1, P = NS; 1,488 ± 229 vs. 1,609 ± 253 pmol · h−1 · l−1, P = NS), acarbose resulted in a significant reduction for both glucose (1.44 ± 0.3 vs. 4.45 ± 0.9 mmol · h−1 · l−1, P = 0.002) and insulin (626.7 ± 104.3 vs. 1,338.3 ± 220.5 pmol · h−1 · l−1, P = 0.003). The reduction in 12-h plasma glucose and insulin AUC on acarbose (11.2 ± 2.1 mmol · h−1 · l−1 and 7.5 ± 0.7 nmol · h−1 · l−1) was significantly greater than that on placebo (4.0 ± 1.6 mmol · h−1 · l−1 and 0.8 ± 0.4 nmol · h−1 · l−1) (P = 0.014 and 0.041). While SSPG was not affected by placebo (13.9 ± 0.4 vs. 13.8 ± 0.3 mmol/l; P = NS), it was significantly improved by acarbose (10.9 ± 1.4 vs. 13.1 ± 1.5 mmol/l, P < 0.004) and was also significantly different from placebo at 4 months (P < 0.02). CONCLUSIONS It is concluded that in subjects with IGT, acarbose treatment decreases postprandial plasma glucose and insulin and improves insulin sensitivity. Acarbose may therefore be potentially useful to prevent the progression of IGT to NIDDM.

[1]  S. Ross,et al.  The Efficacy of Acarbose in the Treatment of Patients with NonInsulin-Dependent Diabetes Mellitus: A Multicenter, Controlled Clinical Trial , 1994, Annals of Internal Medicine.

[2]  R. DeFronzo,et al.  Pathogenesis of NIDDM: A Balanced Overview , 1992, Diabetes Care.

[3]  M. Hanefeld,et al.  Therapeutic Potentials of Acarbose as First-Line Drug in NIDDM Insufficiently Treated With Diet Alone , 1991, Diabetes Care.

[4]  G. Reaven,et al.  Effect of Acarbose on Carbohydrate and Lipid Metabolism in NIDDM Patients Poorly Controlled by Sulfonylureas , 1990, Diabetes Care.

[5]  R. Prager,et al.  Effects of 8-Wk α-Glucosidase Inhibition on Metabolic Control, C-Peptide Secretion, Hepatic Glucose Output, and Peripheral Insulin Sensitivity in Poorly Controlled Type II Diabetic Patients , 1989, Diabetes Care.

[6]  P. Bennett,et al.  The natural history of impaired glucose tolerance in the Pima Indians. , 1988, The New England journal of medicine.

[7]  S. Clissold,et al.  Acarbose , 2022, Drugs.

[8]  A Ward,et al.  Pentoxifylline , 1987, Drugs.

[9]  P. Bennett,et al.  Prevalence of Diabetes and Impaired Glucose Tolerance and Plasma Glucose Levels in U.S. Population Aged 20–74 Yr , 1987, Diabetes.

[10]  P. Hamet,et al.  The effects of sucrose meal on insulin requirement in IDDM and its modulation by acarbose. , 1986, Diabete & metabolisme.

[11]  K. Alberti,et al.  Scope and Specificity of Acarbose in Slowing Carbohydrate Absorption in Man , 1981, Diabetes.

[12]  J. Olefsky,et al.  Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes. , 1981, The American journal of medicine.

[13]  P. Savage,et al.  A Simplified Method Using Somatostatin to Assess In Vivo Insulin Resistance over a Range of Obesity , 1979, Diabetes.

[14]  C. Mahan,et al.  Prospective study of 352 young patients with chemical diabetes. , 1968, The New England journal of medicine.